NCT00036790: Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer |
|
|
| Completed | 1 | | US | doxorubicin hydrochloride, motexafin gadolinium | University of Wisconsin, Madison, National Cancer Institute (NCI) | Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 10/05 | | | |
NCT00734773: Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL |
|
|
| Withdrawn | 1 | 0 | US | Rituximab, Rituxan, Cytarabine, Cytosar-U, Ara-c, Methotrexate, MTX, Rheumatrex, Trexall, Motexafin gadolinium, MGd, Procarbazine hydrochloride, Matulane, Vincristine sulfate, Vincasar PFS, Radiation therapy, Whole Brain Radiation Therapy (WBRT) | Northwestern University, Pharmacyclics LLC. | Brain and Central Nervous System Tumors, Lymphoma, Neurotoxicity | | | | |
